New cocktail of drugs shows promise for tough prostate cancer
NCT ID NCT02913196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe dose of apalutamide when given with the other drugs. Researchers also tracked changes in PSA levels and tumor growth. Because this is a phase 1 study, it primarily looks at safety and dosing, not yet at how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apalutamide, abiraterone acetate, docetaxel, and prednisone
- What this could lead to
- If successful, this could lead to a more effective treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is a very early phase 1 trial with only 16 participants, focused on safety and dosing. The combination may cause significant side effects, and it is unknown if it will improve survival or quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart resistant prostate cancer?
- Could fasting help the immune system fight prostate cancer?
- Could a new PET tracer reveal hidden prostate cancer activity?
- New imaging comparison could improve prostate cancer monitoring
- AI reads biopsies to predict cancer spread
- AI learns from 14,000 prostate scans to spot aggressive cancers